Welcome to our dedicated page for Tarsus Pharmaceuticals SEC filings (Ticker: TARS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, with AI-powered tools to help interpret them. Tarsus is a commercial-stage biopharmaceutical company focused on therapeutics starting with eye care, led by XDEMVY (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis and a lotilaner-based pipeline that includes TP-04 and TP-05.
Through this page, users can access Tarsus’ current and historical filings, including annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically describe the company’s business, risk factors, financial statements, and discussion of results. Current reports on Form 8-K provide details on material events such as quarterly financial results, annual meeting outcomes, and other significant corporate developments. For example, recent 8-K filings reference press releases that set forth Tarsus’ results of operations for specific quarters and describe shareholder voting results at the annual meeting.
Investors can also review proxy statements referenced in 8-K filings to understand proposals submitted to stockholders, including director elections, advisory votes on executive compensation, and ratification of the independent registered public accounting firm. In addition, Form 4 insider transaction reports, when available, can be used to track purchases and sales of TARS shares by directors, officers, and other insiders.
Stock Titan’s AI features summarize lengthy filings, highlight key sections related to revenue dependence on XDEMVY, pipeline development, capital needs, and risk factors, and explain technical language in more accessible terms. Real-time updates from EDGAR ensure that new Tarsus filings, from 10-K and 10-Q reports to 8-K current reports and Form 4 insider filings, appear promptly so users can follow changes in the company’s regulatory and financial profile without manually parsing every document.
Aziz A. Mottiwala reports an intention to sell Common stock. The filing lists 4,330 shares of Common stock to be sold in connection with restricted stock vesting tied to compensation, with the action dated 03/17/2026 and the security shown on NASDAQ.
The filing also reports 4,286 shares of Common stock sold during the prior three months, dated 03/17/2026. The entries identify a brokerage address for Fidelity Brokerage Services LLC.
TARS submitted a Form 144 notice reporting restricted stock vesting and related disposals of common shares. The filing lists 379 common shares tied to a Restricted Stock Vesting event on 03/17/2026. It also records that 375 common shares were sold during the past three months on 03/17/2026 by Elizabeth Yeu-Lin.
Tarsus Pharmaceuticals director William J. Link, PhD sold 12,500 shares of Common Stock in open-market transactions. The sales occurred on 2026-03-16 at weighted-average prices of $68.09, $69.03, and $69.75, under an automatic Rule 10b5-1 trading plan adopted on September 8, 2025. Following these trades, he continues to hold 116,332 shares directly.
Tarsus Pharmaceuticals, Inc. Chief Human Resources Officer Dianne C. Whitfield reported the settlement of vested Restricted Stock Units into common shares. On March 15, 2026, she exercised RSUs covering 23,909 underlying shares, resulting in direct ownership of 47,302 shares of common stock.
The RSUs were granted under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan on March 9, 2022, March 8, 2023, March 7, 2024, and March 5, 2025. Each grant vests in four equal annual installments on March 15 of consecutive years, subject to continuous service.
Tarsus Pharmaceuticals, Inc. reported that General Counsel Bryan Wahl acquired common shares through the settlement of vested restricted stock units (RSUs). On March 15, 2026, multiple RSU awards were exercised, delivering a total of 24,236 shares of common stock at an exercise price of $0.00 per share.
Following these transactions, Wahl held 76,399 shares of Tarsus common stock directly, which includes 451 shares acquired under the company’s Employee Stock Purchase Plan on June 30, 2025. The RSUs were granted between 2022 and 2025 under the 2020 Stock Plan, with 25% of each grant vesting annually on March 15, subject to continued service.
Tarsus Pharmaceuticals, Inc. Chief Operating Officer Seshadri Neervannan reported equity compensation activity tied to restricted stock units. On March 15, 2026, vested RSUs were settled into 26,287 shares of common stock at an exercise price of $0.00 per share.
The RSUs were granted under the Tarsus 2020 Stock Plan across awards from 2022 through 2025, each vesting in four annual 25% installments on March 15, subject to continuous service. After these settlements, Neervannan directly holds 97,104 shares of common stock.
The filing also shows 475 shares of common stock held indirectly by his daughter, with an explicit disclaimer that he does not beneficially own those securities for Section 16 or other purposes.
Tarsus Pharmaceuticals Chief Commercial Officer Aziz Mottiwala acquired 26,482 shares of common stock on March 15, 2026 through the settlement of vested Restricted Stock Units granted under the company’s 2020 Stock Plan. Each RSU converts into one share of common stock at no cash exercise price.
Following these transactions, Mottiwala directly holds 74,536 shares of Tarsus common stock. This total includes 497 shares acquired under the company’s Employee Stock Purchase Plan on June 30, 2025 and December 31, 2025, reflecting ongoing equity-based compensation rather than open-market buying or selling.
Tarsus Pharmaceuticals, Inc. officer Jeffrey S. Farrow reported the settlement of vested Restricted Stock Units into common stock. On March 15, 2026, he acquired 13,042 shares of common stock upon exercise/settlement of RSUs granted under the company’s 2020 Stock Plan.
The filing indicates these RSUs were from grants made on March 7, 2024 and March 5, 2025, each vesting in four equal annual installments every March 15, subject to continued service. Following these transactions, Farrow directly holds 49,746 shares of Tarsus common stock.
Tarsus Pharmaceuticals, Inc. reported that President/CEO and Board Chair Bobak R. Azamian exercised and settled restricted stock units into common shares. On March 15, 2026, he converted RSUs covering 66,274 shares of common stock at a conversion price of $0.00 per share.
After these settlements, his directly held common stock position reported in this filing is 68,024 shares. He also has an indirect holding of 857,991 common shares through the Bobak Azamian Living Trust established April 16, 2018, where he has voting and dispositive power over the shares.
Tarsus Pharmaceuticals Chief Medical Officer Elizabeth Yeu acquired shares through the vesting and settlement of Restricted Stock Units (RSUs). On March 15, 2026, 2,511 RSUs were settled into 2,511 shares of common stock at a conversion price of $0.00 per share.
Following these transactions, she held 7,534 RSUs and 24,452 shares of common stock directly. She also had indirect ownership of 6,360 common shares through a spouse’s Roth IRA and 12,040 common shares through a 401(k) plan.
According to the RSU grant terms, awarded on March 5, 2025 under the 2020 Stock Plan, 25% of the RSUs vest on March 15 of each of 2026, 2027, 2028 and 2029, subject to her continuous service.